{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Personalized+tumor+vaccine&page=3", "query": { "intervention": "Personalized tumor vaccine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Personalized+tumor+vaccine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Personalized+tumor+vaccine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T19:01:19.007Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00082459", "title": "Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "autologous human tumor-derived HSPPC-96", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2002-07", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2012-09-07", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082459" }, { "nct_id": "NCT02287428", "title": "Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Personalized NeoAntigen Peptides", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287428" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT03953235", "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Solid Tumor", "Shared Neoantigen-Positive Solid Tumors" ], "interventions": [ { "name": "GRT-C903", "type": "BIOLOGICAL" }, { "name": "GRT-R904", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gritstone bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-07-18", "completion_date": "2023-03-10", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953235" }, { "nct_id": "NCT06529822", "title": "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Gastroesophageal Adenocarcinoma", "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Synthetic long peptide personalized cancer vaccine", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Signatera or Altera testing", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-03-20", "completion_date": "2034-06-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 3, "location_summary": "Orlando, Florida • St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06529822" }, { "nct_id": "NCT02600949", "title": "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Imiquimod", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sotigalimab", "type": "BIOLOGICAL" }, { "name": "Synthetic Tumor-Associated Peptide Vaccine Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2016-05-11", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600949" }, { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Invasive Breast Lobular Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 138, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT05158621", "title": "A Screening Study Targeting Tumor-specific Antigens", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer", "Stage II/III Colon Cancer" ], "interventions": [ { "name": "blood collection for research (next generation sequencing [NGS])", "type": "PROCEDURE" }, { "name": "blood collection for research (HLA typing)", "type": "PROCEDURE" }, { "name": "blood collection for research (circulating tumor DNA [ctDNA])", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Gritstone bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 22, "start_date": "2021-12-14", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 6, "location_summary": "Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05158621" }, { "nct_id": "NCT03639714", "title": "A Study of a Personalized Neoantigen Cancer Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Colorectal Cancer", "Gastroesophageal Adenocarcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "GRT-C901", "type": "BIOLOGICAL" }, { "name": "GRT-R902", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gritstone bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-02-13", "completion_date": "2022-11-10", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639714" }, { "nct_id": "NCT05010200", "title": "The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "PGV-001", "type": "BIOLOGICAL" }, { "name": "Poly-ICLC", "type": "BIOLOGICAL" }, { "name": "CDX-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ashutosh Kumar Tewari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 27, "start_date": "2022-01-05", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-10T19:01:19.007Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010200" } ] }